Table 2 Aggregated trial characteristics^a,b

Study and Patient characteristics

 Total number of patients

3,219

1,386

1,833

PIK3CA Mutation Testing Methodology, N (%)

 ctDNA testing

18 (54.5%)

9 (52.9%)

9 (56.3%)

 Tissue testing

13 (39.4%)

7 (41.2%)

6 (37.5%)

 Missing

2 (6.1%)

1 (5.9%)

1 (6.3%)

Percentage of Patients with Prior Chemotherapy, median (range)

 Overall^c

67.0 (27.4, 95.4)

64.6 (27.4, 92.0)

72.0 (29.8, 95.4)

 For metastatic disease^c

27.8 (0.0, 35.0)

27.4 (0.0, 34.0)

29.9 (0.0, 35.0)

Median Follow-up Time (Months)

 Overall

14.6 (7.4, 45.1)

14.6 (8.9, 45.1)

14.5 (7.4, 45.1)

Study treatment

 Any Fulvestrant

23 (69.7%)

12 (70.6%)

11 (68.8%)

 Abemaciclib + Fulvestrant

2 (6.1%)

1 (5.9%)

1 (6.3%)

 Placebo + Fulvestrant

19 (57.6%)

10 (58.8%)

9 (56.3%)

 Palbociclib + Fulvestrant

2 (6.1%)

1 (5.9%)

1 (6.3%)

 Everolimus + Exemestane

4 (12.1%)

2 (11.8%)

2 (12.5%)

 Placebo + Exemestane

4 (12.1%)

2 (11.8%)

2 (12.5%)

 Other

2 (6.1%)

1 (5.9%)

1 (6.3%)

Survival outcomes

 Median progression-free survival (months)

5.6 (1.4, 23.4)

5.4 (1.4, 19.0)

6.2 (1.7, 23.4)

 6 Month Survival Rate (%)^e

46.2 (10.8, 93.4)

43.0 (10.8, 91.0)

53.5 (19.8, 93.4)

 12 Month Survival Rate (%)^e

31.7 (5.8, 76.4)

29.2 (18.8, 66.7)

32.6 (5.8, 76.4)

 18 Month Survival Rate (%)^e

22.7 (3.2, 64.8)

20.0 (18.4, 51.3)

26.4 (3.2, 64.8)

 Median overall survival (months)^d

32.2 (19.6, 55.5)

26.9 (19.6, 44.5)

37.8 (23.5, 55.5)